Medical Devices · Cervical Cancer Screening · FDA & NMPA Certified
The SurePath™ LBC system uses a proprietary sample collection method and patented centrifugal sedimentation technology — the third-generation cytology testing method. It delivers automated, standardised, high-throughput slide preparation with industry-leading specimen adequacy rates and the highest FDA-certified cancer precursor detection rate compared to conventional Pap smears.
SurePath™ liquid-based cytology is the world’s most clinically validated cervical screening technology, backed by over two decades of large-scale FDA clinical evidence. Its unique sedimentation-based slide preparation preserves the three-dimensional cellular structure, producing a clear, uniform monolayer free from obscuring blood, mucus and inflammatory cells.
The PrepStain™ Slide Processor automates the entire workflow — from sample pre-treatment and cell enrichment to slide preparation and Papanicolaou staining — completing a batch of 24 slides in just 40 minutes. Each slide uses an independent reagent cartridge to eliminate cross-contamination, and the closed waste-liquid system reduces fume exposure in the laboratory.
| Model | PrepStain™ Slide Processor |
|---|---|
| Dimensions | 770 × 580 × 650 mm (W × D × H) |
| Weight | 65 kg |
| Throughput | 1–24 slides per batch · 40 min per batch of 24 |
| Slide Preparation Method | Sedimentation (preserves 3D cell structure) |
| Staining Method | Independent single-slide drop staining (no cross-contamination) |
| Applications | Gynaecological LBC · Non-gynaecological cytology · Immunocytochemistry (dual / single stain) |
| Reagent System | Independent cartridge per slide; closed waste-liquid system |
| Operating Temperature | 25–30 °C |
| Regulatory Status | FDA 510(k) cleared · NMPA registered · CE IVD |
| Compatible Media | SurePath™ preservative fluid |
Vaginal Infection Testing
The Affirm™ VPIII is the industry's first fully automated system using DNA probe technology to simultaneously detect the three most common vaginal pathogens — Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC) and Trichomonas Vaginalis (TV) — from a single sample. It has become the standard method for vaginal infection testing recommended by the US Centers for Disease Control and Prevention (CDC).
HPV Testing
The Viper LT™ is a benchtop molecular platform that automates DNA extraction, RT-PCR amplification, detection and result reporting — minimising manual intervention. Paired with the Onclarity™ HPV Assay, it delivers genotyping results for 14 high-risk HPV types, with individual identification of 6 types, from the same SurePath™ vial used for liquid-based cytology — one sample, two tests.
DNA Ploidy Analysis
The DNA Ploidy Analysis System combines with SurePath™ liquid-based cytology to create a dual-modality cervical cancer screening solution — one preparation, two tests. Automated quantitative DNA ploidy analysis detects chromosomal abnormalities at the molecular level, identifying occult lesions that conventional cytology may miss, and raising CIN2+ detection sensitivity to 96.9%.
Hong Kong Origins Investment Limited — Professional cross-border trade solutions for medical devices, specialising in cervical cancer screening, women's health diagnostics and IVD products.
Copyright © 2026 Hong Kong Origins Investment Limited. All rights reserved. Privacy Policy